Cytokine News and Research

RSS

Celldex to present results from CDX-301 Phase 1 study in healthy volunteers

Celldex Therapeutics, Inc. today announced an upcoming data presentation at the American Society of Hematology 54th Annual Meeting and Exposition to be held in Atlanta, GA from December 8 through December 11, 2012.

6 Nov 2012

Inhibition of NOX4 enzyme plays an important role in liver fibrosis

Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) have led a study published in PLoS One showing that the inhibition of a family member of NADPH oxidase enzyme, NOX4, plays an important role in liver fibrosis.

5 Nov 2012

NJH researchers discover novel target for treatment of food allergies

Researchers at National Jewish Health have discovered a novel target for the treatment of food allergies. Erwin Gelfand, MD, and his colleagues report in the October 2012 issue of the Journal of Allergy and Clinical Immunology that levels of the enzyme Pim 1 kinase rise in the small intestines of peanut-allergic mice. Inhibiting activity of Pim 1 markedly reduced the allergic response to peanuts.

2 Nov 2012

Obese patients may have advantages in certain health situations

Although obesity is linked to a variety of health risks, new research indicates that obese patients may have an advantage over nonobese patients in certain health situations, including septic shock and acute asthma exacerbation.

22 Oct 2012

Weill Cornell Medical College researcher wins 2012 William B. Coley Award

Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College and provost for medical affairs of Cornell University, is a winner of the 2012 William B. Coley Award for Distinguished Research in Basic Immunology from the Cancer Research Institute for her outstanding achievements in immunology and cancer research.

19 Oct 2012

Cytokine levels altered in FEP, schizophrenia patients

Levels of certain cytokines are altered in patients with first-episode psychosis and patients with schizophrenia, research shows.

17 Oct 2012

Highlights of Mount Sinai research at Neuroscience 2012

Researchers from Mount Sinai School of Medicine are presenting important discoveries on the involvement of the immune system and dopamine cells in the onset of depression at Neuroscience 2012, the Society for Neuroscience's 42nd annual meeting on October 13 -17 in New Orleans, and are available for interviews.

15 Oct 2012

Researchers discover mechanism by which magnesium reduces cytokine production

Magnesium sulfate is given to many pregnant women to treat preterm labor and preeclampsia and was recently shown to prevent cerebral palsy; however little is known about how it works. Researchers at Case Western Reserve University School of Medicine recently discovered the mechanism by which magnesium reduces the production of cytokines.

10 Oct 2012

Modulating immune response to injury could accelerate regeneration of peripheral nerves

Modulating immune response to injury could accelerate the regeneration of severed peripheral nerves, a new study in an animal model has found. By altering activity of the macrophage cells that respond to injuries, researchers dramatically increased the rate at which nerve processes regrew.

4 Oct 2012

Three USU doctoral students to receive Henry M. Jackson Fellowships

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has selected three promising Uniformed Services University of the Health Sciences (USU) doctoral students to receive fellowships for the 2012-13 academic year. The program, established in 1988, includes two Henry M. Jackson Fellowships and one Val G. Hemming Fellowship. Each fellow receives a stipend and travel support.

28 Sep 2012

OncoSec establishes UW as second enrolling site for OMS-I100 Phase II metastatic melanoma trial

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that it has established the University of Washington (UW) as the second enrolling site for its Phase II metastatic melanoma clinical trial (OMS-I100).

25 Sep 2012

Genome-wide epigenomic screening can pinpoint thyroid disease-associated variants

Genome-wide epigenomic screening can pinpoint disease-associated variants and identify novel genetic-epigenetic interactions in autoimmune thyroid diseases, according to new data presented at the 82nd Annual Meeting of the American Thyroid Association (ATA) in Québec City, Québec, Canada.

24 Sep 2012

GSK3 inhibition protects against gum disease

Treatment with the cell-permeable glycogen synthase kinase -3β-specific enzyme inhibitor SB216763 successfully suppresses alveolar bone loss in mice infected with the main periodontal pathogen, Porphyromonas gingivalis, report researchers.

20 Sep 2012

ProImmune launches ProStorm in vitro cytokine release assay

ProImmune Ltd., a leader in services for understanding immune responses, announced today the commercial launch of ProStorm, an in vitro cytokine release assay, which can help assess the likelihood of first infusion reactions to novel therapeutics.

18 Sep 2012

KaloBios commences KB003 Phase 2 trial in severe asthma

KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB003, the company's anti-GM-CSF Humaneered monoclonal antibody, in subjects with severe asthma uncontrolled by corticosteroids.

12 Sep 2012

Interleukin-18 plays a key role in inflammation

The naturally occurring cytokine interleukin-18, or IL-18, plays a key role in inflammation and has been implicated in serious inflammatory diseases for which the prognosis is poor and there are currently limited treatment options.

7 Sep 2012

Clinical trial to test combination of two drugs in treating fibromyalgia

A chronic pain condition and numerous gastrointestinal disorders may all be caused by a virus. That's a Tuscaloosa-based surgeon's theory likely headed for a clinical trial early next year and one drawing support from a University of Alabama researcher who studies how viruses replicate.

6 Sep 2012

Phase 1b trial validates efficacy of Pulmatrix PUR118 to treat COPD

Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, today announced top line results from a clinical study showing that the novel inhaled therapeutic, PUR118, demonstrated anti-inflammatory efficacy and was well-tolerated in two Phase 1b studies in patients with chronic obstructive pulmonary disease (COPD).

5 Sep 2012

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Pfizer Inc. announced today that the European Commission (EC) has granted marketing authorization for INLYTA (axitinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

4 Sep 2012

Salivary IL-6 could predict recurrence after surgery in mouth cancer patients

Salivary levels of the proinflammatory cytokine interleukin-6 could be a useful predictor for locoregional recurrence in oral squamous cell carcinoma patients who are treated surgically, report researchers.

23 Aug 2012